Targeting Osteoblastic Bone Metastasis with a Novel Site Restricted Gene Therapy
Final rept. 1 Jun 2001-31 May 2004
TEXAS UNIV AT DALLAS SOUTHWESTERN MEDICAL CENTER
Pagination or Media Count:
Continuing from the previous two years work on this project, encouraging data was also obtained in year 3. Effectiveness of the Ad- BSP-Ela viral contrast was again demonstrated in the intraosseous model of prostate cancer bone metastasis. Further tests were completed and, as such, it appears that low dose systemic taxotere administration in combination with the viral construct Ad-BSP-Ela may have better efficacy and long-term cancer control, based upon serum PSA as a biochemical recurrence marker. This metastasis model in vivo data corresponds nicely to the previously reported in vitro data which was presented in year 2 progress report After much effort, we were able to construct the Ad-hTERT-Ela construct. The cloning data and purification analysis is presented in this report. This construct will be available for future testing and future attempts at funding. The most striking nature of this research is the apparent synergism with the chemogene therapy approach in the in vivo metastasis model. It appears that systemic Ad-BSP-Ela virus along with taxotere has a striking effect on control of the prostate intraosseous tumors. The likely most efficacious combination in humans afflicted with prostate cancer metastasis is Ad-BSP-Ela virus and low-dose taxotere with dexamethasone as evidenced by our data presented herein.
- Medicine and Medical Research